Bimervax from HIPRA Human Health has been authorised in the UK after meeting the Medicines & Healthcare products Regulatory Agency’s (MHRA) required safety, quality and effectiveness standards. It becomes the ninth Covid-19 vaccine to be authorised by the UK’s independent medicines regulator. Bimervax combines… Read More
Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP). The results show UB-612 elicits superior neutralising antibody titers and seroconversion rates against… Read More
Global Phase III topline data is expected later this year for a new class of Covid-19 booster vaccine. Vaxxinity has completed enrollment for the trial, co-sponsored by the Coalition for Epidemic Preparedness Innovations (CEPI). Its UB-612 will be evaluated as a heterologous booster vaccine to mRNA, adeno-vectored, and inactivated primary… Read More
GSK and Sanofi have reported positive efficacy data from a co-developed vaccine targeting the Omicron variant of Covid-19. The report makes GSK and Sanofi the first companies to have a vaccine candidate for the Omicron variant which has demonstrated efficacy. Specifically, the companies’ B.1.351… Read More
Moderna has dosed the first participant in a Phase II study of the company’s Omicron-specific booster candidate (mRNA-1273.529). Additionally, Moderna announced the publication of neutralising antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine. The mRNA-1273.529 trial This extension… Read More
A study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, suggests that an additional dose of a Covid-19 vaccine is safe in adults who had previously received a full regimen of any of three Covid-19 vaccines granted Emergency Use Authorization… Read More
A third ‘booster’ dose of Covid-19 vaccine successfully raises antibody levels that neutralise the Omicron variant, according to laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published as a Research letter in The Lancet. The results Researchers found that antibodies generated in people… Read More
The first results of an early trial of a multivariant Covid-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response. The results US-based biotechnology company Gritstone bio, in collaboration with The University of Manchester and Manchester University… Read More
